JP2010511729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511729A5 JP2010511729A5 JP2009540451A JP2009540451A JP2010511729A5 JP 2010511729 A5 JP2010511729 A5 JP 2010511729A5 JP 2009540451 A JP2009540451 A JP 2009540451A JP 2009540451 A JP2009540451 A JP 2009540451A JP 2010511729 A5 JP2010511729 A5 JP 2010511729A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- progestagen
- pharmaceutically acceptable
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 149
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims description 84
- 239000000583 progesterone congener Substances 0.000 claims description 84
- 239000003937 drug carrier Substances 0.000 claims description 37
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 30
- 229960003387 progesterone Drugs 0.000 claims description 15
- 239000000186 progesterone Substances 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 12
- 206010013774 Dry eye Diseases 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 9
- 210000000744 eyelid Anatomy 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 description 78
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 4
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 4
- 229960004296 megestrol acetate Drugs 0.000 description 4
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 4
- 229940053934 norethindrone Drugs 0.000 description 4
- 229960001652 norethindrone acetate Drugs 0.000 description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 150000003146 progesterones Chemical class 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/634,347 US20080132475A1 (en) | 2006-12-05 | 2006-12-05 | Treatment for dry eye |
| PCT/US2007/086515 WO2008070726A2 (en) | 2006-12-05 | 2007-12-05 | Treatment for dry eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511729A JP2010511729A (ja) | 2010-04-15 |
| JP2010511729A5 true JP2010511729A5 (enExample) | 2012-01-05 |
Family
ID=39476533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540453A Pending JP2010511730A (ja) | 2006-12-05 | 2007-12-05 | テストステロンおよびプロゲスターゲンを用いたドライアイのための処置 |
| JP2009540451A Pending JP2010511729A (ja) | 2006-12-05 | 2007-12-05 | ドライアイのための処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540453A Pending JP2010511730A (ja) | 2006-12-05 | 2007-12-05 | テストステロンおよびプロゲスターゲンを用いたドライアイのための処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080132475A1 (enExample) |
| EP (2) | EP2124958A4 (enExample) |
| JP (2) | JP2010511730A (enExample) |
| KR (2) | KR20090104813A (enExample) |
| CN (2) | CN101636164A (enExample) |
| AU (1) | AU2009202711A1 (enExample) |
| BR (2) | BRPI0720172A2 (enExample) |
| CA (2) | CA2671698A1 (enExample) |
| EA (2) | EA200900663A1 (enExample) |
| IL (1) | IL199094A0 (enExample) |
| MX (2) | MX2009005994A (enExample) |
| WO (2) | WO2008070728A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5894364B2 (ja) * | 2007-08-16 | 2016-03-30 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 眼および付属器組織の炎症を処置するための治療組成物 |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| US20110144077A1 (en) * | 2008-08-05 | 2011-06-16 | Thomas Cotter | Treatment of retinal degeneration |
| UA114705C2 (uk) * | 2011-01-26 | 2017-07-25 | Аллерган, Інк. | Андрогенна композиція для лікування офтальмологічного захворювання |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| MX362185B (es) * | 2012-07-27 | 2019-01-08 | Glia Llc | Composiciones y tratamiento para enfermedades y trastornos del ojo. |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| WO2014152385A2 (en) | 2013-03-15 | 2014-09-25 | Glia, Llc | Cranial delivery of pharmaceuticals |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
| ES2986830T3 (es) * | 2014-10-20 | 2024-11-12 | Oyster Point Pharma Inc | Métodos de tratamiento de afecciones oculares |
| US20180071313A1 (en) * | 2015-04-03 | 2018-03-15 | Santen Pharmaceutical Co., Ltd. | Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| EP3509585B1 (en) | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| TW202131927A (zh) * | 2019-11-13 | 2021-09-01 | 美商葛莉亞有限責任公司 | 睾固酮組合物 |
| WO2023107796A1 (en) * | 2021-12-11 | 2023-06-15 | The Regents Of The University Of California | Ophthalmic formulations for macular degeneration |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
| JPS59184135A (ja) * | 1983-04-04 | 1984-10-19 | Teijin Ltd | グリセリンピログルタミン酸エステル類を含有する医薬品組成物 |
| US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| DE3514724A1 (de) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
| US4914088A (en) * | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| USRE34578E (en) * | 1990-05-07 | 1994-04-05 | Lubkin; Virginia | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| ZA912797B (en) * | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US5958912A (en) * | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
| ES2139005T3 (es) * | 1992-04-21 | 2000-02-01 | Schepens Eye Res Inst | Terapia ocular con androgeno en el sindrome de sjogren. |
| US5688765A (en) * | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
| US5366739A (en) * | 1992-08-06 | 1994-11-22 | Deo Corporation | Method of ophthalmic drug delivery |
| CA2142103C (en) * | 1992-08-28 | 2003-07-08 | Haim Aviv | Submicron emulsions as ocular drug delivery vehicles |
| WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| CA2261263C (en) * | 1996-07-22 | 2008-10-07 | The Victoria University Of Manchester | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| ATE293960T1 (de) * | 1997-02-28 | 2005-05-15 | Minnesota Mining & Mfg | Transdermale vorrichtung zur verabreichungvon von testosteron |
| US5869090A (en) * | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| FR2774587B1 (fr) * | 1998-02-09 | 2000-03-10 | Oreal | Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique |
| US6348210B1 (en) * | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| CA2376797C (en) * | 1999-06-11 | 2011-03-22 | Watson Pharmaceuticals, Inc. | Administration of non oral androgenic steroids to women |
| WO2001041806A1 (en) * | 1999-12-07 | 2001-06-14 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
| US6630175B1 (en) * | 2000-06-29 | 2003-10-07 | Johnson & Johnson Consumer Companies, Inc. | Method of reducing eye irritation |
| AU2002245104B2 (en) * | 2000-12-11 | 2006-08-17 | Testocreme, Llc | Topical testosterone formulations and associated methods |
| US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| WO2004045510A2 (en) * | 2002-11-15 | 2004-06-03 | Panaseca, Inc. | Methods and compositions for alleviating dry eyes |
| US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| US7960350B2 (en) * | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
| US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| JP2008530127A (ja) * | 2005-02-09 | 2008-08-07 | マクサイト， インコーポレイテッド | 眼の処置のための処方物 |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
-
2006
- 2006-12-05 US US11/634,347 patent/US20080132475A1/en not_active Abandoned
-
2007
- 2007-12-05 CN CN200780049235A patent/CN101636164A/zh active Pending
- 2007-12-05 WO PCT/US2007/086517 patent/WO2008070728A2/en not_active Ceased
- 2007-12-05 EA EA200900663A patent/EA200900663A1/ru unknown
- 2007-12-05 KR KR1020097013348A patent/KR20090104813A/ko not_active Withdrawn
- 2007-12-05 EA EA200900662A patent/EA200900662A1/ru unknown
- 2007-12-05 CA CA002671698A patent/CA2671698A1/en not_active Abandoned
- 2007-12-05 BR BRPI0720172-9A patent/BRPI0720172A2/pt not_active IP Right Cessation
- 2007-12-05 EP EP07865244A patent/EP2124958A4/en not_active Withdrawn
- 2007-12-05 JP JP2009540453A patent/JP2010511730A/ja active Pending
- 2007-12-05 CA CA002671769A patent/CA2671769A1/en not_active Abandoned
- 2007-12-05 MX MX2009005994A patent/MX2009005994A/es not_active Application Discontinuation
- 2007-12-05 BR BRPI0719918-0A2A patent/BRPI0719918A2/pt not_active IP Right Cessation
- 2007-12-05 KR KR1020097013349A patent/KR20090104814A/ko not_active Withdrawn
- 2007-12-05 EP EP07865242A patent/EP2101785A4/en not_active Withdrawn
- 2007-12-05 MX MX2009005993A patent/MX2009005993A/es not_active Application Discontinuation
- 2007-12-05 WO PCT/US2007/086515 patent/WO2008070726A2/en not_active Ceased
- 2007-12-05 CN CN200780049245A patent/CN101636165A/zh active Pending
- 2007-12-05 JP JP2009540451A patent/JP2010511729A/ja active Pending
-
2009
- 2009-06-02 IL IL199094A patent/IL199094A0/en unknown
- 2009-07-03 AU AU2009202711A patent/AU2009202711A1/en not_active Abandoned
-
2013
- 2013-12-23 US US14/139,243 patent/US20140113889A1/en not_active Abandoned
-
2020
- 2020-02-18 US US16/793,581 patent/US20210008079A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511729A5 (enExample) | ||
| JP2010511730A5 (enExample) | ||
| CA2928969C (en) | Compositions and methods for ophthalmic and/or other applications | |
| US10292955B2 (en) | Composition for external use preparation with improved transdermal permeability | |
| AU2020203213A1 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| JP2024057010A5 (enExample) | ||
| JP7374986B2 (ja) | 眼を治療するための組成物及び方法 | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| WO2004071529A3 (en) | Uses of anti-insulin-like growth factor i receptor antibodies | |
| CN107582605A (zh) | 眼用组合物 | |
| JP2005537238A (ja) | ポリヒドロキシアルカンの脂肪酸エステルおよびピリジンカルボキシ誘導体の新規複合体 | |
| KR20090042956A (ko) | 안과 경피 흡수형 제제 | |
| JP2016527306A (ja) | 胆汁酸−脂肪酸抱合体を含む抗老化組成物 | |
| WO2000018316A3 (en) | Sustained release, and comfortable ophthalmic composition and method for ocular therapy | |
| CN103108640B (zh) | 包含烟酸腺嘌呤二核苷酸磷酸或该烟酸腺嘌呤二核苷酸磷酸的衍生物的药学或者化妆料组合物 | |
| KR102006950B1 (ko) | 양모ㆍ육모 촉진용 화장료 조성물 | |
| KR20210065968A (ko) | 심미적 피부 상태를 치료하기 위한 철 킬레이팅 화합물 | |
| JP2011529936A (ja) | キトサンおよびジカルボン酸を含む、酒さ疾患を治療するための組成物 | |
| FR2518882A1 (fr) | Composition therapeutique, a base de monophosphate d'inosine, pour le traitement des troubles d'accommodation de l'oeil | |
| JP2004010598A (ja) | 皮膚外用剤 | |
| JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
| AU2007200216A1 (en) | Skin formulation usable as a therapeutic application for the treatment of general skin disorders and a method of preparation thereof | |
| JPH07233088A (ja) | 局所外用剤 | |
| WO2016159351A1 (ja) | 涙腺ドラッグデリバリーシステム | |
| CN105055184A (zh) | 一种具有祛眼袋功效的组合物及其应用 |